We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy.
- Authors
Hińcza-Nowak, Kinga; Kowalik, Artur; Walczyk, Agnieszka; Pałyga, Iwona; Gąsior-Perczak, Danuta; Płusa, Agnieszka; Kopczyński, Janusz; Chrapek, Magdalena; Góźdź, Stanisław; Kowalska, Aldona
- Abstract
Medullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapies that restore anticancer activity. Little is known about the immunological phenomena underlying MTC. Here, we examined the expression profile of 395 genes associated with MTC. The study included 51 patients diagnosed with MTC at a single center. Bioinformatical analysis revealed that CD276 expression in MTC cells was at least three-fold higher than that in normal tissue. The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276.
- Subjects
MEDULLARY thyroid carcinoma; ANTINEOPLASTIC agents; GENE expression profiling; DIAGNOSIS; IMMUNOTHERAPY; MONOCLONAL antibodies; CANCER cells
- Publication
Genes, 2021, Vol 12, Issue 10, p1534
- ISSN
2073-4425
- Publication type
Article
- DOI
10.3390/genes12101534